Literature DB >> 20930418

Genetic polymorphisms of FCGRT encoding FcRn in a Japanese population and their functional analysis.

Akiko Ishii-Watabe1, Yoshiro Saito, Takuo Suzuki, Minoru Tada, Maho Ukaji, Keiko Maekawa, Kouichi Kurose, Nahoko Kaniwa, Jun-ichi Sawada, Nana Kawasaki, Teruhide Yamaguchi, Takako Eguchi Nakajima, Ken Kato, Yasuhide Yamada, Yasuhiro Shimada, Teruhiko Yoshida, Takashi Ura, Miyuki Saito, Kei Muro, Toshihiko Doi, Nozomu Fuse, Takayuki Yoshino, Atsushi Ohtsu, Nagahiro Saijo, Tetsuya Hamaguchi, Haruhiro Okuda, Yasuhiro Matsumura.   

Abstract

Neonatal Fc receptor (FcRn) plays an important role in regulating IgG homeostasis in the body. Changes in FcRn expression levels or activity caused by genetic polymorphisms of FCGRT, which encodes FcRn, may lead to interindividual differences in pharmacokinetics of therapeutic antibodies. In this study, we sequenced the 5'-flanking region, all exons and their flanking regions of FCGRT from 126 Japanese subjects. Thirty-three genetic variations, including 17 novel ones, were found. Of these, two novel non-synonymous variations, 629G>A (R210Q) and 889T>A (S297T), were found as heterozygous variations. We next assessed the functional significance of the two novel non-synonymous variations by expressing wild-type and variant proteins in HeLa cells. Both variant proteins showed similar intracellular localization as well as antibody recycling efficiencies. These results suggested that at least no common functional polymorphic site with amino acid change was present in the FCGRT of our Japanese population.

Entities:  

Mesh:

Substances:

Year:  2010        PMID: 20930418     DOI: 10.2133/dmpk.dmpk-10-rg-067

Source DB:  PubMed          Journal:  Drug Metab Pharmacokinet        ISSN: 1347-4367            Impact factor:   3.614


  6 in total

Review 1.  FcRn: The Architect Behind the Immune and Nonimmune Functions of IgG and Albumin.

Authors:  Michal Pyzik; Timo Rath; Wayne I Lencer; Kristi Baker; Richard S Blumberg
Journal:  J Immunol       Date:  2015-05-15       Impact factor: 5.422

2.  Functional polymorphisms in rhesus macaque FCGRT and β2-m.

Authors:  Zhanna Shubin; Yutaka Tagaya; Bhawna Poonia
Journal:  Immunogenetics       Date:  2017-08-07       Impact factor: 2.846

3.  Atezolizumab and Bevacizumab in Patients with Unresectable Hepatocellular Carcinoma: Pharmacokinetic and Safety Assessments Based on Hepatic Impairment Status and Geographic Region.

Authors:  Colby S Shemesh; Phyllis Chan; Hui Shao; Derek-Zhen Xu; Daniel Combs; Shweta Vadhavkar; René Bruno; Benjamin Wu
Journal:  Liver Cancer       Date:  2021-06-10       Impact factor: 11.740

Review 4.  Potential Sources of Inter-Subject Variability in Monoclonal Antibody Pharmacokinetics.

Authors:  Katherine L Gill; Krishna K Machavaram; Rachel H Rose; Manoranjenni Chetty
Journal:  Clin Pharmacokinet       Date:  2016-07       Impact factor: 6.447

5.  Epistane, an anabolic steroid used for recreational purposes, causes cholestasis with elevated levels of cholic acid conjugates, by upregulating bile acid synthesis (CYP8B1) and cross-talking with nuclear receptors in human hepatocytes.

Authors:  José Vicente Castell; Ramiro Jover; Petar D Petrov; Leonor Fernández-Murga; Isabel Conde; Teresa Martínez-Sena; Carla Guzmán
Journal:  Arch Toxicol       Date:  2020-01-01       Impact factor: 5.153

6.  Lack of ethnic differences in the pharmacokinetics and pharmacodynamics of evolocumab between Caucasian and Asian populations.

Authors:  Chen Wang; Qingshan Zheng; Mingqiang Zhang; Hong Lu
Journal:  Br J Clin Pharmacol       Date:  2018-10-17       Impact factor: 4.335

  6 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.